Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:SKYE NASDAQ:THAR NASDAQ:VTVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.86-5.3%$1.09$0.73▼$10.95$115.52M1.693.01 million shs1.55 million shsSKYESkye Bioscience$0.73-6.8%$0.76$0.57▼$5.75$27.33M3.03208,589 shs128,531 shsTHARTharimmune$3.26-9.9%$3.49$0.95▼$9.08$123M1.431.48 million shs890,211 shsVTVTvTv Therapeutics$36.49+2.8%$35.94$14.00▼$44.00$139.79M0.2659,572 shs65,401 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-5.32%-4.43%-12.23%-42.66%-87.35%SKYESkye Bioscience-6.75%-10.85%-8.07%-7.32%-66.27%THARTharimmune-9.94%+2.19%-4.96%-32.08%+127.40%VTVTvTv Therapeutics+2.82%+13.64%-4.28%-1.99%+71.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.86-5.3%$1.09$0.73▼$10.95$115.52M1.693.01 million shs1.55 million shsSKYESkye Bioscience$0.73-6.8%$0.76$0.57▼$5.75$27.33M3.03208,589 shs128,531 shsTHARTharimmune$3.26-9.9%$3.49$0.95▼$9.08$123M1.431.48 million shs890,211 shsVTVTvTv Therapeutics$36.49+2.8%$35.94$14.00▼$44.00$139.79M0.2659,572 shs65,401 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-5.32%-4.43%-12.23%-42.66%-87.35%SKYESkye Bioscience-6.75%-10.85%-8.07%-7.32%-66.27%THARTharimmune-9.94%+2.19%-4.96%-32.08%+127.40%VTVTvTv Therapeutics+2.82%+13.64%-4.28%-1.99%+71.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/ASKYESkye Bioscience 2.57Moderate Buy$9.801,251.35% UpsideTHARTharimmune 1.00SellN/AN/AVTVTvTv Therapeutics 2.86Moderate Buy$53.0045.25% UpsideCurrent Analyst Ratings BreakdownLatest SKYE, THAR, VTVT, and AIFC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026VTVTvTv Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/13/2026VTVTvTv Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/27/2026VTVTvTv Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026VTVTvTv Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.003/12/2026VTVTvTv Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.003/11/2026VTVTvTv Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$49.00 ➝ $49.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M4.40N/AN/A$9.07 per share0.09SKYESkye BioscienceN/AN/AN/AN/A$0.26 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/AVTVTvTv Therapeutics$1.02M140.95N/AN/A$22.84 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-1,386.90%-50.52%-45.05%N/ASKYESkye Bioscience-$55.92M-$1.44N/AN/AN/AN/A-217.27%-162.39%N/ATHARTharimmune-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%6/3/2026 (Estimated)VTVTvTv Therapeutics-$26.97M-$0.93N/AN/AN/AN/A3.96%2.86%N/ALatest SKYE, THAR, VTVT, and AIFC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/13/2026Q1 2026VTVTvTv Therapeutics$0.21$1.65+$1.44$1.65$20.00 million$36.84 million5/11/2026Q1 2026SKYESkye Bioscience-$0.29-$0.32-$0.03-$0.32N/AN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/10/2026Q4 2025SKYESkye Bioscience-$0.29-$0.36-$0.07-$0.36N/AN/A3/10/2026Q4 2025VTVTvTv Therapeutics-$1.0880-$0.58+$0.5080-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/AVTVTvTv TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.010.570.57SKYESkye BioscienceN/A1.781.78THARTharimmuneN/A4.984.98VTVTvTv TherapeuticsN/A14.3614.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%SKYESkye Bioscience21.09%THARTharimmune1.16%VTVTvTv Therapeutics17.51%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%SKYESkye Bioscience6.20%THARTharimmune6.70%VTVTvTv Therapeutics5.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170127.17 million126.90 millionN/ASKYESkye Bioscience1135.14 million32.97 millionOptionableTHARTharimmune237.73 million35.20 millionNot OptionableVTVTvTv Therapeutics93.94 million3.70 millionNot OptionableSKYE, THAR, VTVT, and AIFC HeadlinesRecent News About These CompaniesvTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen NextMay 17 at 1:53 PM | finance.yahoo.comWhy vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%May 16, 2026 | aaii.comAvTv Therapeutics (NASDAQ:VTVT) Upgraded at Zacks ResearchMay 16, 2026 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Raised to Buy at Wall Street ZenMay 16, 2026 | americanbankingnews.comvTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be SustainableMay 15, 2026 | zacks.comvTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 15, 2026 | americanbankingnews.comvTv Therapeutics Expands At-The-Market Share Program CapacityMay 13, 2026 | tipranks.comvTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comvTv Therapeutics (VTVT) Projected to Post Earnings on WednesdayMay 11, 2026 | marketbeat.comvTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by AnalystsMay 10, 2026 | marketbeat.comvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comvTv Therapeutics to Participate in Upcoming May Investor ConferencesMay 7, 2026 | globenewswire.comvTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below Fifty Day Moving Average - What's Next?May 6, 2026 | marketbeat.comvTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest UpdateApril 28, 2026 | marketbeat.comvTv Therapeutics (NASDAQ:VTVT) Stock Passes Below Fifty Day Moving Average - Time to Sell?April 24, 2026 | marketbeat.comWall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?April 20, 2026 | zacks.comvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 7, 2026 | globenewswire.comvTv Therapeutics, Inc. Class AApril 6, 2026 | edition.cnn.comWall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a BetApril 2, 2026 | zacks.comvTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin AdvancementsMarch 17, 2026 | insidermonkey.comWall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to TradeMarch 17, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKYE, THAR, VTVT, and AIFC Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.86 -0.05 (-5.32%) As of 05/19/2026 03:57 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Skye Bioscience NASDAQ:SKYE$0.73 -0.05 (-6.75%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.90%) As of 05/19/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Tharimmune NASDAQ:THAR$3.26 -0.36 (-9.94%) As of 05/18/2026Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.vTv Therapeutics NASDAQ:VTVT$36.49 +1.00 (+2.82%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$36.70 +0.21 (+0.59%) As of 05/19/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
